ES2624722T3 - Vacuna mucosa que emplea nanogel catiónico - Google Patents

Vacuna mucosa que emplea nanogel catiónico Download PDF

Info

Publication number
ES2624722T3
ES2624722T3 ES09823688.8T ES09823688T ES2624722T3 ES 2624722 T3 ES2624722 T3 ES 2624722T3 ES 09823688 T ES09823688 T ES 09823688T ES 2624722 T3 ES2624722 T3 ES 2624722T3
Authority
ES
Spain
Prior art keywords
vaccine
nanogel
mucosal
cationic
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09823688.8T
Other languages
English (en)
Spanish (es)
Inventor
Kazunari Akiyoshi
Hiroshi Kiyono
Yoshikazu Yuki
Tomonori Nochi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellectual Property Strategy Network Inc
Original Assignee
Intellectual Property Strategy Network Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellectual Property Strategy Network Inc filed Critical Intellectual Property Strategy Network Inc
Application granted granted Critical
Publication of ES2624722T3 publication Critical patent/ES2624722T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES09823688.8T 2008-10-31 2009-10-30 Vacuna mucosa que emplea nanogel catiónico Active ES2624722T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008281065 2008-10-31
JP2008281065A JP5344558B2 (ja) 2008-10-31 2008-10-31 カチオン性ナノゲルを用いる粘膜ワクチン
PCT/JP2009/068647 WO2010050578A1 (ja) 2008-10-31 2009-10-30 カチオン性ナノゲルを用いる粘膜ワクチン

Publications (1)

Publication Number Publication Date
ES2624722T3 true ES2624722T3 (es) 2017-07-17

Family

ID=42128937

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09823688.8T Active ES2624722T3 (es) 2008-10-31 2009-10-30 Vacuna mucosa que emplea nanogel catiónico

Country Status (5)

Country Link
US (2) US20110206729A1 (enExample)
EP (1) EP2345419B8 (enExample)
JP (1) JP5344558B2 (enExample)
ES (1) ES2624722T3 (enExample)
WO (1) WO2010050578A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2153820A4 (en) 2007-05-14 2013-12-25 Konica Minolta Holdings Inc LIPOSOM AND METHOD FOR THE PRODUCTION OF LIPOSOMY
JP5344558B2 (ja) 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
US20120196349A1 (en) * 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
EP2663294B1 (en) 2011-01-11 2015-09-30 Capsugel Belgium NV New hard capsules comprising pullulan
DK2750683T4 (da) * 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
WO2013085021A1 (ja) * 2011-12-09 2013-06-13 株式会社林原 抗体産生増強用の組成物
JP6310720B2 (ja) * 2014-02-17 2018-04-11 知的財産戦略ネットワーク株式会社 肺炎球菌経鼻ワクチン
WO2015186678A1 (ja) * 2014-06-04 2015-12-10 第一三共株式会社 粘膜ワクチン用アジュバント
US20170319706A1 (en) * 2014-11-18 2017-11-09 Dow Global Technologies Llc Delivering a drug to a mucosal surface
CN110381992A (zh) 2016-12-03 2019-10-25 Uab研究基金会 组合了肺炎球菌表面蛋白A的选择的α螺旋结构域和脯氨酸富集结构域的肺炎球菌疫苗
HRP20250979T1 (hr) 2017-04-14 2025-10-24 Capsugel Belgium Nv Pululan kapsule
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
CN107583059B (zh) * 2017-10-31 2021-03-30 宁夏医科大学 一种可包载量子点的阳离子脂质体流感疫苗及其制备方法
JP2020019754A (ja) * 2018-08-03 2020-02-06 国立研究開発法人農業・食品産業技術総合研究機構 ウシ乳房炎に対する粘膜ワクチン組成物
KR20210040387A (ko) * 2018-08-03 2021-04-13 고쿠리츠다이가쿠호우진 도쿄다이가쿠 세포성 면역을 유도하는 경비 백신
US20240181033A1 (en) * 2021-03-30 2024-06-06 The University Of Tokyo Nanogel-coated vaccine
US12409135B2 (en) 2021-12-08 2025-09-09 Immunitybio, Inc. Neoepitope vaccine delivery vehicle and methods of making the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63270555A (ja) 1987-04-28 1988-11-08 日鉄鉱業株式会社 ロ−ルクラツシヤ
JPH05339169A (ja) 1992-03-03 1993-12-21 Dai Ichi Seiyaku Co Ltd 経口ワクチン
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US6656481B1 (en) * 1996-09-06 2003-12-02 Mitsubishi Chemical Corporation Vaccinal preparations
EP1026174B1 (en) 1998-08-31 2005-05-18 Nof Corporation High-purity polysaccharide containing hydrophobic groups and process for producing the same
JP4599550B2 (ja) 2004-04-09 2010-12-15 国立大学法人 東京医科歯科大学 ナノゲル工学によるハイブリッドゲルの調製とバイオマテリアル応用
WO2006049032A1 (ja) 2004-11-01 2006-05-11 Tokyo Medical And Dental University ナノゲル－アパタイト複合体の調製
JP4550555B2 (ja) 2004-11-17 2010-09-22 国立大学法人 東京医科歯科大学 量子ドット（Ｑｄｏｔ）−ナノゲル複合体の調製
CA2637194A1 (en) 2006-01-18 2007-07-26 National University Corporation Tokyo Medical And Dental University Biomaterial for osteogenesis containing osteogenesis promoter and nanogel
JP2007252304A (ja) * 2006-03-24 2007-10-04 Tokyo Medical & Dental Univ ナノゲルを用いたタンパク質の細胞内導入法
JP5428017B2 (ja) * 2007-03-23 2014-02-26 国立大学法人 熊本大学 ワクチン剤
JP2008281065A (ja) 2007-05-09 2008-11-20 Nsk Ltd 玉軸受
GB0717864D0 (en) * 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
JP5344558B2 (ja) 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン

Also Published As

Publication number Publication date
JP2010105968A (ja) 2010-05-13
JP5344558B2 (ja) 2013-11-20
EP2345419B8 (en) 2017-04-26
US8961983B2 (en) 2015-02-24
WO2010050578A1 (ja) 2010-05-06
EP2345419A4 (en) 2013-07-10
US20110206729A1 (en) 2011-08-25
EP2345419A1 (en) 2011-07-20
EP2345419B1 (en) 2017-02-22
US20140370056A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
EP2345419B1 (en) Mucosal vaccine using cationic nanogel
ES2212145T3 (es) Administracion de sustancias por la mucosa a mamiferos.
CA2212382C (en) Cochleate delivery vehicles
ES2855474T3 (es) Composiciones de liposomas que comprenden un adyuvante que activa o incrementa la actividad de TLR2 y usos del mismo
ES2365988T3 (es) Agentes inmunoestimulantes no específicos.
Zhang et al. Curdlan sulfate–O-linked quaternized chitosan nanoparticles: Potential adjuvants to improve the immunogenicity of exogenous antigens via intranasal vaccination
ES2369550T3 (es) Formulación de adyuvante para administración en mucosas.
US20060252717A1 (en) Sphingoid polyalkylamine conjugates for vaccination
Yadav et al. Nanovaccines formulation and applications-a review
Azuar et al. Cholic acid-based delivery system for vaccine candidates against group A streptococcus
ES2525127T3 (es) Utilización de las glicosilceramidas para aumentar la respuesta inmunitaria a los antígenos
Yu et al. The pH-responsive zeolitic imidazolate framework nanoparticle as a promising immune-enhancing adjuvant for anti-caries vaccine
CN107200788A (zh) 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
US20060171956A1 (en) Sphingoid polyalkylamine conjugates for hepatitis B virus vaccination
BRPI0707556A2 (pt) veÍculo para vacina
KR20140141229A (ko) 점막 점착성 폴리감마글루탐산 나노마이셀 및 이를 이용한 약물 전달체
KR20070117551A (ko) 점막 백신의 전달용 펩티드
WO2013085021A1 (ja) 抗体産生増強用の組成物
WO2004047805A1 (es) Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios.
CN112789056B (zh) 粘膜佐剂
EP2514438B1 (en) ADJUVANT CONTAINING ß-HEMATIN
Soni et al. Overview of Nanovaccines and Nanoadjuvants
Sloat et al. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice
CN100469393C (zh) 用于接种的sphingoid聚烷基胺缀合物
Kumar et al. Role of Supramolecules in Vaccine Development